论文部分内容阅读
本研究对冠心病患者应用噻氯吡啶对血小板聚集功能（ｐｌａｔｅｌｅｔａｇｇｒｅｇａｔｉｏｎ，ＰＡｇ）及血浆纤维蛋白原（ｆｉｂｒｉｎｏｇｅｎ，Ｆｇ）水平的影响进行探讨并与乙酰水杨酸（ａｃｅｔｙｌｓａｌｉｃｙｌｉａａｃｉｄ，ＡＳＡ）进行比较。冠心病（ｃｏｒｏｎａｒｙａｒｔｅｒｙｄｉｓｅａｓｅ，ＣＡＤ）患者１２０例，随机分为三组，即乙酰水杨酸组、噻氯吡啶组及对照组。噻氯吡啶组患者服用噻氯吡啶（抵克力得，ＴＩＣＬＩＤ）２５０ｍｇ，每日一次，连用４周；乙酰水杨酸组患者口服乙酰水杨酸７５ｍｇ，每日一次，连用４周。对照组患者于受试前２周内未服用抗血小板制剂。两用药组及对照组均于晨间空腹抽取静脉血，测定ＰＡｇ及Ｆｇ水平。用药组于用药４周末测定上述指标。ＰＡｇ测定采用比浊法，聚集诱导剂分别为肾上腺素（ｅｐｉｎｅｐｈｒｉｎｅ，Ｅｐｎ），二磷酸腺苷（ａｄｅｎｏｓｉｎｅｄｉｐｈｏｓｐｈａｔｅ，ＡＤＰ）及胶原（ｃｏｌａｇｅｎ，Ｃｏｌ），ＰＡｇ以加用诱导剂后５ｍｉｎ血小板聚集率表示。统计学处理，各组间比较采用ｓｔｕｄｅｎｔＴ检验，Ｐ＜０．０５为差异显著。结果表明，与对照组相比，乙酰水杨酸及噻氯吡啶组ＡＤＰ、肾上腺素及胶原诱导的ＰＡｇ均明显?
In this study, we investigated the effects of ticlopyr on platelet aggregation (PAg) and fibrinogen (Fg) levels in patients with coronary heart disease and compared them with acetylsalicylia acid (ASA). 120 patients with coronary artery disease (CAD) were randomly divided into three groups: acetylsalicylic acid group, ticlopyridine group and control group. Ticlopidine patients taking Ticlopidine (Ticlide, TICLID) 250mg, once daily for 4 weeks; acetylsalicylic acid group of patients taking oral acetylsalicylic acid 75mg once daily for 4 weeks. Patients in the control group did not take antiplatelet agents within 2 weeks before the test. Both groups and control group were fasting venous blood samples were taken morning, determination of PAg and Fg levels. The medication group in the medication 4 weeks to determine the above indicators. PAg was measured by turbidimetric method. The concentrations of epinephrine (Epn), adenosine diphosphate (ADP) and collagen (colagen) and PAg were used as aggregation inducing agents to show platelet aggregation rate at 5min after adding inducer. Statistical analysis, comparison between groups using studentT test, P <0.05 was significant difference. The results showed that compared with the control group, acetylsalicylic acid and ticlopyridine ADP, adrenaline and collagen-induced PAg were significantly?